These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27686015)

  • 1. Toward an Effective Ebola Virus Vaccine.
    Keshwara R; Johnson RF; Schnell MJ
    Annu Rev Med; 2017 Jan; 68():371-386. PubMed ID: 27686015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically modified rabies virus-vectored Ebola virus disease vaccines are safe and induce efficacious immune responses in mice and dogs.
    Shuai L; Wang X; Wen Z; Ge J; Wang J; Zhao D; Bu Z
    Antiviral Res; 2017 Oct; 146():36-44. PubMed ID: 28822816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ebola vaccine trials: progress in vaccine safety and immunogenicity.
    Matz KM; Marzi A; Feldmann H
    Expert Rev Vaccines; 2019 Dec; 18(12):1229-1242. PubMed ID: 31779496
    [No Abstract]   [Full Text] [Related]  

  • 6. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
    Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP
    Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
    Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
    Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
    Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
    Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
    Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.
    Wong G; Qiu X
    Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the development of vaccines for Ebola virus disease.
    Ohimain EI
    Virus Res; 2016 Jan; 211():174-85. PubMed ID: 26596227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Overview of Ebola virus vaccine].
    Yang L; Li J; Gao GF; Liu W
    Sheng Wu Gong Cheng Xue Bao; 2015 Jan; 31(1):1-23. PubMed ID: 26021076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
    Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
    Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
    Wu S; Kroeker A; Wong G; He S; Hou L; Audet J; Wei H; Zhang Z; Fernando L; Soule G; Tran K; Bi S; Zhu T; Yu X; Chen W; Qiu X
    J Infect Dis; 2016 Oct; 214(suppl 3):S326-S332. PubMed ID: 27493239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
    Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA
    Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
    Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
    J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.
    Falzarano D; Feldmann F; Grolla A; Leung A; Ebihara H; Strong JE; Marzi A; Takada A; Jones S; Gren J; Geisbert J; Jones SM; Geisbert TW; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1082-9. PubMed ID: 21987745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.
    Johnson RF; Kurup D; Hagen KR; Fisher C; Keshwara R; Papaneri A; Perry DL; Cooper K; Jahrling PB; Wang JT; Ter Meulen J; Wirblich C; Schnell MJ
    J Infect Dis; 2016 Oct; 214(suppl 3):S342-S354. PubMed ID: 27456709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines.
    Patel A; Reuschel EL; Kraynyak KA; Racine T; Park DH; Scott VL; Audet J; Amante D; Wise MC; Keaton AA; Wong G; Villarreal DO; Walters J; Muthumani K; Shedlock DJ; de La Vega MA; Plyler R; Boyer J; Broderick KE; Yan J; Khan AS; Jones S; Bello A; Soule G; Tran KN; He S; Tierney K; Qiu X; Kobinger GP; Sardesai NY; Weiner DB
    J Infect Dis; 2019 Jan; 219(4):544-555. PubMed ID: 30304515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.